Biomarker ID | 1195 |
PMID | 23918943 |
Year | 2013 |
Biomarker | Methylation Status of MOB3B |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethylated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: univariate : [HR = 1.351 (95% CI: 0.793-2.303), P-value=0.268] |
Effect on Pathways | Pathways include: F2RL1 knockdown 96h HT29, NR1D2 knockdown 96h HT29, CAMK2D knockdown 96h HT29, AGTR1 knockdown 96h MCF7, FLT3 knockdown 96h MCF7 |
Experiment | Biochemical recurrence |
Type of Biomarker | Prognostic |
Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
Senstivity | NA |
Specificity | NA |
AUC | 0.93 |
Accuracy | NA |
Level Of Significance | P < 0.001 |
Method Used | quantitative methylation specific PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | MOB3B |